Edmond de Rothschild Investment Partners, an independent, family-owned group focused on private banking and asset management, has held the €125m first close and launched the fourth fund in its BioDiscovery franchise dedicated to investing in Life Sciences in France and in Europe.
Backers include existing and new institutional investors. The final target of the fund is about €200m by the end of the year
BioDiscovery 4, which will deploy the same strategy of its previous funds, plans to make 15 to 20 investments in life science companies across all stages of development. The investments will be made both in therapeutic drug development companies and a combination of medical technology and molecular diagnostic companies. The fund will invest mainly in Europe.